Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13758572 | 0.81 | LMNA (0.44) | PTGS1KAT6ATET2POLBGAA | |
| SCHEMBL1491209 | 0.80 | CA2 (0.50) | CA2CA12CA1CA9PTGS1 | |
| SCHEMBL28011329 | 0.79 | LMNA (0.43) | PTGS1KAT6ATET2POLBGAA | |
| SCHEMBL3818556 | 0.79 | KAT6A (0.40) | CA2PTGS1KAT6APOLBGAA | |
| SCHEMBL29799524 | 0.79 | KAT6A (0.40) | CA2PTGS1KAT6APOLBGAA | |
| SCHEMBL1128576 | 0.79 | ENPP2 (0.45) | PTGS1KAT6A | |
| SCHEMBL29556118 | 0.78 | PTGS1 (0.48) | CA2CA12CA1CA9PTGS1 | |
| SCHEMBL789994 | 0.78 | PTGS1 (0.48) | CA2CA12CA1CA9PTGS1 | |
| SCHEMBL31235349 | 0.77 | CA2 (0.50) | CA2CA12CA1CA9PTGS1 | |
| SCHEMBL21603106 | 0.77 | CA2 (0.50) | CA2CA12CA1CA9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2308840-A1 | GPCR agonists | Prosidion Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-1089988-B1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| CN-101253151-A | GPCR agonists | PROSIDION LTD (GB) | 2008-08-27 | — | — | CN | disclosed |
| EP-1910290-A2 | GPCR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| EP-1044364-B8 | METHOD FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMA INC (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1044364-B1 | METHOD FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARM PROD INC (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007003962-A2 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| EP-1089988-A4 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1044364-A4 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARM PROD INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6599753-B1 | Quantifying a solid-phase reaction; obtain chemical intermediate, incubate with fluorine compound, expose to nuclear magnetic resonance, monitor intensity, compare to control | AVENTIS PHARMACEUTICALS INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1089988-A1 | FLUOROPHENYL RESIN COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1044364-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | Aventis Pharmaceuticals Products Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999067228-A1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | CA2 3541/4885CA12 4792/4885CA1 4864/4885 |
| US-20100063081-A1 | CPCR Agonists | GPR119, GCGR, GLP1R | CA2 1487/4885CA12 3987/4885CA1 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.